'RELIABLE' PERSPECTIVE: Moderna CEO Warns People 'May Need Fourth CV Shot' as Efficacy of Boosters Likely to Decline Over Time

Source: CNBC

Published: January 6, 2022

By: Spencer Kimball

KEY POINTS

• Moderna CEO Stephane Bancel said the efficacy of boosters against Covid-19 will likely decline over time, and some people may need a fourth shot by the fall.
• “I would expect that it’s not going to hold great,” Bancel said, during a Goldman Sachs interview, referring to the strength of the single booster shots.
• A random mutation could change the course of the pandemic again, Bancel warned.

Moderna CEO Stephane Bancel on Thursday said the efficacy of boosters against Covid-19 will likely decline over time, and people may need a fourth shot in the fall to increase their protection.

A nurse prepares a syringe with a dose of the Moderna coronavirus disease (COVID-19) vaccine at Enfermera Isabel Zendal hospital in Madrid, Spain, July 23, 2021. - Juan Medina | Reuters

Bancel said people who received their boosters last fall will likely have enough protection to get them through the winter, when new infections surge as people gather indoors to escape the cold.

RELATED: 

REVELATION: Top Mitch McConnell Staffer Leads Pfizer Lobbyists to Protect Vaccine Patent, Block Bill Holding Big Pharma Accountable for Fraud

IGNORING PAST EXPERIENCES: Netherlands Announces Plan to Give People Up to Six Doses of CV Vax Without Knowing the Result

However, Bancel said the efficacy of boosters will probably decline over the course of several months, similar to what happened with the first two doses. The Moderna chief was interviewed by Goldman Sachs during the investment bank’s health-care CEO conference.

“I will be surprised when we get that data in the coming weeks that it’s holding nicely over time — I would expect that it’s not going to hold great,” Bancel said, referring to the strength of the booster shots.

An unprecedented surge of infections from the highly contagious omicron variant is currently spreading worldwide. In the U.S., the seven-day average is now more than 574,000 new cases daily, according to a CNBC analysis of data from Johns Hopkins University.

Bank of America senior analyst explains why he’s bearish on Moderna compared to Pfizer

The Moderna CEO said governments, including the U.K. and South Korea, are already ordering the doses in preparation. “I still believe we’re going to need boosters in the fall of ’22 and forward,” Bancel said, adding that people who are older or have underlying health conditions might need annual boosters for years to come.

“We have been saying that we believe first this virus is not going away,” Bancel said. “We’re going to have to live with it.”

RELATED: 

HONESTY DEFERRED: FDA Requests to Hide Pfizer Vaccine Data for 55 Years; Citizens Outraged

LEGAL CONCEPTS: Federal Law Prohibits Mandates of Emergency Use CV Vaccines, Tests, Masks

Moderna published preliminary data last month that showed its currently authorized 50 microgram booster shot increased the antibodies that block infection from omicron 37-fold. A 100 microgram booster increased those antibodies 83-fold.

Booster shots are playing an increasingly important role in public health strategies to control the virus, with protection from the original two shots having taken a significant blow from omicron.

Data from the United Kingdom found that Moderna and Pfizer’s two-dose vaccines are only about 10% effective at preventing symptomatic infection from omicron 20 weeks after the second dose.

The same study, published by the U.K. Health Security Agency, found that booster doses are up to 75% effective at preventing symptomatic infection two weeks after receiving the shot.

However, the efficacy of booster shots starts to decline after about four weeks, according to the study. Boosters were 55% to 70% effective at preventing infection at weeks five to nine, and 40% to 50% effective 10 weeks after receiving the shot.

Pfizer CEO Albert Bourla told CNBC last month that people will likely need a fourth dose, and the shot may be needed sooner than expected due to omicron’s virulence.

Bancel, during the Goldman Sachs interview, said omicron could accelerate the transition from the acute crisis caused by the virus to an endemic phase where enough people have immune protection so that Covid isn’t as disruptive to public life.

Read more at: CNBC.com

Discerning the Mystery is a website dedicated to awakening and educating the people to their true potential of mental, spiritual, emotional, and physical growth. It can be difficult work, but if just one person benefits from these efforts, it is entirely worth it. 

If you enjoy what you read here, please give the post a like and share on social media. Also, if you enjoyed this article, please consider leaving a donation.

Feel free to send us an email and tell us what you think. If you have any suggestions or subjects you would like to see discussed, please let us know.

Thank you for your support.